ABSTRACT

Treating dyspnoea in a COPD patient with lung cancer

Chronic obstructive pulmonary disease (COPD) and lung cancer are tobacco-related diseases that often coexist. The increased morbidity and mortality because of both diseases should draw our attention to improving their diagnosis. The similar clinical presentations of the two conditions can mask their early symptoms, and chest X-rays should be obtained regularly in patients with COPD. If an abnormality is found, work-up should be extended. At present, thanks to the cancer diagnosis and therapy card (DILO), which can be issued at any stage in the diagnostic process, patients can be diagnosed and treated as soon as possible. The diagnostic process ends with a histopathological diagnosis and staging of lung cancer according to the TNM classification. Lung cancer risk factors include, in addition to smoking, low FEV1, emphysema, and obesity. Severe COPD can be a limitation for diagnosis and radical cancer treatment. Dyspnoea in COPD and lung cancer patients may be related directly and indirectly to the cancer, treatment procedures and associated diseases. The cause of dyspnoea determines the treatment. Treatment of dyspnoea in terminally ill patients is also an important issue.

Piśmiennictwo

1. https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf

2. Krzakowski M, Jassem J, Antczak A, et al. Cancer of the lung, pleura and mediastinum. Oncol Clin Pract 2019;15. doi: 10.5603/OCP.2018.0056

3. Azad N, Rojanasakul Y, Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J Toxicol Environ B Crit Rev 2008;11(1):1-15

4. Nizankowska-Mogilnicka E, Mejza F, Buist AS, et al. Prevalence of COPD and tobacco smoking in Malopolska region – results from the BOLD study in Poland. Pol Arch Med Wewn 2007;117(9):402-10

5. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med 2011;32(4):605-44

6. Obecny stan zwalczania nowotworów w Polsce. Dokument w ramach projektu „Strategia walki z rakiem w Polsce w latach 2015-2024”. Polskie Towarzystwo Onkologiczne, 16 maja 2014 r.

7. Chazan R (red.). Standardy diagnostyczno-terapeutyczne w chorobach układu oddechowego – wskazówki praktyczne. α-medica press 2018

8. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009;34(2):380-6

9. Fry JS, Hamling JS, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline to lung cancer risk. BMC Cancer 2012;12:498

10. Maskey-Warzechowska M, Domagała-Kulawik J, Rubinsztajn R, et al. Lung cancer in COPD – a clinical analysis. Pol Arch Med Wew 2002;108(2):769-75

11. Husebø GR, Nielsen R, Hardie J, et al. Risk factors for lung cancer in COPD – results from the Bergen COPD cohort study. Respir Med 2019;152:81-8

12. Schwartz AG, Cote ML. Epidemiology of Lung Cancer. Adv Exp Med Biol 2016;893:21-41

13. MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology 2017;284(1):228-43

14. Detterbeck FC. The eighth edition TNM stage classification for lung cancer: What does it mean on main street? J Thorac Cardiovasc Surg 2018;155(1):356-9

15. Licker MJ, Widikker I, Robert J et al. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends. Ann Thorac Surg 2006;81(5):1830-7

16. Franczuk M, Wesołowski S. Assessment of respiratory function in the qualification for lung cancer surgery. Pneumonol Alergol Pol 2015;83(1):74-82

17. von Groote-Bidlingmaier F, Koegelenberg CF, Bolliger CT. Functional evaluation before lung resection. Clin Chest Med 2011;32(4):773-82

18. Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer. 3rd edition. American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013;143(5 Suppl.):e166S-e90S

19. Dudgeon DJ, Kristjanson L, Sloan JA et al. Dyspnea in cancer patients: prevalence and associated factors. J Pain Symptom Manage 2001;21(2):95-102

20. Leppert W. Leczenie Objawów ze strony ukladu oddechowego u chorych na nowotwory. Nowiny Lekarskie 2011;80(1):32-46

21. Nava S, Ferrer M, Esquinas A, et al. Palliative use of non-invasive ventilation in end-of-life patients with solid tumours: a randomised feasibility trial. Lancet Oncol 2013;14(3):219-27

22. López-Saca JM, Centeno C. Opioids prescription for symptoms relief and the impact on respiratory function: updated evidence. Curr Opin Support Palliat Care 2014;8(4):383-90

Do góry